乳业科学与技术 ›› 2026, Vol. 49 ›› Issue (5): 1-9.DOI: 10.7506/rykxyjs1671-5187-20260316-026

• 基础研究 •    

基于动物实验与人体试验的复合益生菌粉调节肠道菌群功能评价

胡孟琦,齐悦,刘晶晶,张楠,刘欢,易紫容,刘洋   

  1. (1.北京中医药大学中药学院,北京 102488;2.牡丹江医科大学公共卫生学院,黑龙江牡丹江 157011;3.中国药品检定研究院,北京 100050)
  • 发布日期:2026-11-08
  • 基金资助:
    国家自然科学基金面上项目(81973295)

Evaluation of the Regulatory Effect of Formulated Probiotic Powder on the Gut Microbiota Based on Animal and Human Studies

HU Mengqi, QI Yue, LIU Jingjing, ZHANG Nan, LIU Huan, YI Zirong, LIU Yang   

  1. (1. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China; 2. School of Public Health, Mudanjiang Medical University, Mudanjiang 157011, China; 3. National Institutes for Drug Control, Beijing 100050, China)
  • Online:2026-11-08

摘要: 本研究旨在通过动物实验与人体试验,系统评价复合益生菌粉对于人体肠道菌群的调节功能及食用安全性。将48只BALB/c雄性小鼠随机分为对照组和低、中、高剂量组,连续灌胃复合益生菌粉14 d,检测其体质量、肠道菌群及粪便短链脂肪酸(short-chain fatty acids,SCFAs)含量。同时,招募102名健康受试者,随机分为试食组和对照组,试食组每日服用复合益生菌粉2 g,持续14 d,观察其一般身体状况、血尿常规、生化指标及肠道菌群变化。动物实验结果表明,与对照组相比,中、高剂量组能显著增加小鼠粪便中有益菌乳杆菌和双歧杆菌菌落数(P<0.05);中、高剂量组显著提高丙酸、丁酸、戊酸含量(P<0.05),高剂量组极显著提高异丁酸含量(P<0.01),且对小鼠体质量无不良影响。人体试验结果显示,试食组受试者粪便中有益菌乳杆菌菌落数显著增加(P<0.05),且能维持菌群整体稳定,不会引起其他菌群(肠杆菌、肠球菌、产气荚膜梭菌、拟杆菌)剧烈波动。此外,血常规、生化指标等安全性指标均在正常范围内且与对照组无显著差异(P>0.05)。综上,复合益生菌粉能够选择性促进目标益生菌生长,促进SCFAs生成,并能维持肠道菌群平衡且具有良好食用安全性,为该复合益生菌粉调节肠道菌群的科学应用提供了动物及临床人体的研究数据。

关键词: 复合益生菌粉;肠道菌群;短链脂肪酸;动物实验;人体试验

Abstract: This study aims to systematically evaluate the efficacy of a formulated probiotic powder in regulating the intestinal microbiota and its safety for consumption through animal experiments and human studies. Forty-eight BALB /c male mice were randomly divided into a control group and low-, medium-, and high-dose groups. All mice, except the control group, were administered the probiotic consortium via gavage for 14 consecutive days, during which their body mass, intestinal microbiota, and fecal short-chain fatty acid (SCFA) contents were measured. Additionally, 102 healthy subjects were recruited and randomly assigned to either an intervention group or a control group. The intervention group consumed 2 g of the probiotic powder daily for 14 days. Changes in the general physical condition, routine blood and urine parameters, biochemical parameters, and intestinal microbiota of the subjects were observed. Animal studies showed that compared with the control group, the medium- and high-dose groups exhibited significantly increased counts of Lactobacillus and Bifidobacterium (P < 0.05) and significantly elevated levels of propionic acid, butyric acid, and valeric acid ( P < 0.05) in mouse feces, while the high-dose group showed a highly significant increase in isobutyric acid levels ( P < 0.01), with no adverse effects on mouse body mass. Human trials demonstrated a significant increase in the beneficial bacterium Lactobacillus in the feces of the intervention group ( P < 0.05), while the microbial community remained generally stable 收稿日期:2026-03-16 基金项目:国家自然科学基金面上项目(81973295) 第一作者简介:胡孟琦(2003— )(ORCID: 0009-0005-6194-873X),女,硕士研究生,研究方向为药靶结合动力学与药物 代谢。E-mail: 1208865189@qq.com *通信作者简介:刘洋(1973—)(ORCID: 0009-0004-8113-8278),男,教授,博士,研究方向为药靶结合动力学与药物代谢。 E-mail: liuyang@bucm.edu.cn without significant fluctuations in other bacterial groups (e.g., Enterobacteriaceae, Enterococcus, Clostridium perfringens , and Bacteroides). Furthermore, safety parameters such as routine blood and biochemical indicators remained within normal ranges and showed no significant differences compared to the control group ( P > 0.05). In conclusion, the formulated probiotic powder selectively promotes the growth of target probiotics, enhances SCFA production, maintains intestinal microbiota balance, and is safe to consume. This study provides animal and clinical evidence supporting the scientific application of this formulated probiotic powder in modulating the intestinal microbiota.

Key words: formulated probiotic powder; gut microbiota; short-chain fatty acids; animal experiments; human trials

中图分类号: